DE69524094T2 - Verwendung von isolierten domänen des typ-iv-kollagens zur modifikation von zell- und gewebeinteraktionen - Google Patents

Verwendung von isolierten domänen des typ-iv-kollagens zur modifikation von zell- und gewebeinteraktionen

Info

Publication number
DE69524094T2
DE69524094T2 DE69524094T DE69524094T DE69524094T2 DE 69524094 T2 DE69524094 T2 DE 69524094T2 DE 69524094 T DE69524094 T DE 69524094T DE 69524094 T DE69524094 T DE 69524094T DE 69524094 T2 DE69524094 T2 DE 69524094T2
Authority
DE
Germany
Prior art keywords
cell
mesoglea
collagen
type
insulated type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69524094T
Other languages
English (en)
Other versions
DE69524094D1 (de
Inventor
Michael P Sarras Jr
Billy G Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas Medical Center
Original Assignee
University of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas Medical Center filed Critical University of Kansas Medical Center
Application granted granted Critical
Publication of DE69524094D1 publication Critical patent/DE69524094D1/de
Publication of DE69524094T2 publication Critical patent/DE69524094T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE69524094T 1994-06-30 1995-06-30 Verwendung von isolierten domänen des typ-iv-kollagens zur modifikation von zell- und gewebeinteraktionen Expired - Fee Related DE69524094T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/268,969 US5567609A (en) 1994-06-30 1994-06-30 Use of isolated domains of type IV collagen to modify cell and tissue interactions
PCT/US1995/008299 WO1996000582A1 (en) 1994-06-30 1995-06-30 The use of isolated domains of type iv collagen to modify cell and tissue interactions

Publications (2)

Publication Number Publication Date
DE69524094D1 DE69524094D1 (de) 2002-01-03
DE69524094T2 true DE69524094T2 (de) 2002-04-18

Family

ID=23025295

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69524094T Expired - Fee Related DE69524094T2 (de) 1994-06-30 1995-06-30 Verwendung von isolierten domänen des typ-iv-kollagens zur modifikation von zell- und gewebeinteraktionen
DE69532835T Expired - Fee Related DE69532835T2 (de) 1994-06-30 1995-06-30 Verwendung von isolierten Domänen des Typ-IV-Kollagens zur Modifikation von Zell- und Gewebeinteraktionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69532835T Expired - Fee Related DE69532835T2 (de) 1994-06-30 1995-06-30 Verwendung von isolierten Domänen des Typ-IV-Kollagens zur Modifikation von Zell- und Gewebeinteraktionen

Country Status (9)

Country Link
US (7) US5567609A (de)
EP (2) EP0767676B1 (de)
AT (2) ATE262922T1 (de)
AU (1) AU3000895A (de)
DE (2) DE69524094T2 (de)
DK (2) DK1129721T3 (de)
ES (2) ES2164160T3 (de)
PT (2) PT767676E (de)
WO (1) WO1996000582A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567609A (en) 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
US6440729B1 (en) * 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
EP0878480A1 (de) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller Verfahren zur Förderung der Nerven-Regenerierung
AU748751B2 (en) * 1998-03-27 2002-06-13 University Of Kansas Medical Center The use of isolated domains of type IV collagen to modify cell and tissue interactions
US6759047B1 (en) 1998-06-17 2004-07-06 Beth Israel Deaconess Hospital Corp. Anti-angiogenic proteins and methods of use thereof
US6962974B1 (en) 1998-06-17 2005-11-08 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
IL140239A0 (en) * 1998-06-17 2002-02-10 Beth Israel Hospital Anti-angiogenic proteins and methods of use thereof
US7387779B2 (en) 1998-06-17 2008-06-17 Beth Israel Deaconess Medical Center Anti-angiogenic proteins and fragments and methods of use thereof
US20010018579A1 (en) 1998-12-18 2001-08-30 Walter Klemp Disposable absorbent garment having stretchable side waist regions
WO2000059532A1 (en) * 1999-04-01 2000-10-12 Biostratum, Inc. The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
US6893812B2 (en) * 2000-05-30 2005-05-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Three-dimensional ex vivo angiogenesis system
CN100447155C (zh) * 2001-05-23 2008-12-31 中国科学院上海上海生命科学研究院 具有抑制内皮细胞生长活性的重组人内皮生长抑制蛋白
EP1573025A4 (de) 2001-07-27 2006-07-19 Univ Kansas Medical Center Kristallstruktur des typ-iv-collagen-nc1-domäne-hexamers
WO2004067762A2 (en) * 2003-01-27 2004-08-12 University Of Kansas Medical Center Crystallized structure of type iv collagen nc1 domain hexamer
WO2004100769A2 (en) * 2003-05-09 2004-11-25 Falco Frank J Methods for using gadolinium as a contrast media
US7432413B2 (en) 2005-12-16 2008-10-07 The Procter And Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US8057450B2 (en) 2006-03-31 2011-11-15 The Procter & Gamble Company Absorbent article with sensation member
US8491558B2 (en) 2006-03-31 2013-07-23 The Procter & Gamble Company Absorbent article with impregnated sensation material for toilet training
US8664467B2 (en) 2006-03-31 2014-03-04 The Procter & Gamble Company Absorbent articles with feedback signal upon urination
EP2088979A2 (de) 2006-12-04 2009-08-19 The Procter & Gamble Company Saugfähige artikel mit grafischen elementen
US9012160B2 (en) * 2008-06-16 2015-04-21 Abraham Amir Monitoring skin metabolism products for evaluating burn injury
WO2013170433A1 (en) 2012-05-15 2013-11-21 The Procter & Gamble Company Absorbent article having characteristic waist end

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021404A (en) 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
US6440729B1 (en) * 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen

Also Published As

Publication number Publication date
AU3000895A (en) 1996-01-25
ATE209043T1 (de) 2001-12-15
ATE262922T1 (de) 2004-04-15
US5691182A (en) 1997-11-25
PT1129721E (pt) 2004-07-30
US6419924B1 (en) 2002-07-16
US6448222B1 (en) 2002-09-10
PT767676E (pt) 2002-03-28
ES2217050T3 (es) 2004-11-01
EP1129721A3 (de) 2001-11-14
DE69532835D1 (de) 2004-05-06
US6384012B1 (en) 2002-05-07
DK1129721T3 (da) 2004-06-28
EP1129721A2 (de) 2001-09-05
EP1129721B1 (de) 2004-03-31
US5567609A (en) 1996-10-22
ES2164160T3 (es) 2002-02-16
DK0767676T3 (da) 2002-05-21
WO1996000582A1 (en) 1996-01-11
US20030013194A1 (en) 2003-01-16
EP0767676B1 (de) 2001-11-21
DE69532835T2 (de) 2005-02-10
DE69524094D1 (de) 2002-01-03
US5856184A (en) 1999-01-05
US6680293B2 (en) 2004-01-20
EP0767676A1 (de) 1997-04-16

Similar Documents

Publication Publication Date Title
DE69524094D1 (de) Verwendung von isolierten domänen des typ-iv-kollagens zur modifikation von zell- und gewebeinteraktionen
NZ319646A (en) Use of a rar-y-specific agonist ligand for increasing the rate of apoptosis
DE69717065T2 (de) Verwendung von thermochromen Flüssigkristallen in Diagnosemethoden mit Reflektrometrie
DE69017921T2 (de) Lactoferrinhydrolysat zur Verwendung als tyrosinagehemmendes Mittel.
DE69520861D1 (de) Gerät zur Herstellung von Vliesstoffen mit Reliefmustern
DE69221060D1 (de) Verwendung von Emzymen und Flockungsmitteln zur Erhöhung der Entwässerungsneigung von Papierpulpe
NO20003414L (no) Anvendelse av PPAR-<ypsilon> aktivatorer i dermatologi
DE1100751T1 (de) Herstellung von anionischen nanokompositen und ihre verwendung als retentions- und entwässerungshilfsmittel bei der papierherstellung
DE69404373T2 (de) Verwendung von 4-,4- und 5-, oder 4- und 6-substituierten Resorcin-Derivaten in kosmetischen oder dermopharmazeutischen Depigmentierungsmitteln
DE69221443D1 (de) Flüssigkristallichtventil und Informationsprozessor unter Verwendung desselben
DE59309589D1 (de) Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen
DE69712578T2 (de) Verwendung mindestens eines in 6-Stellung substituierten Pyrimidin-3-oxids zur Stimulierung von Tyrosinase
DE69023231T2 (de) IC-Karte mit verbesserter Umschaltung der Stromversorgung.
ATE227995T1 (de) Verwendung von pseudopterosin zur förderung der wundheilung
DE69919684D1 (de) Verwendung von isolierten domänen des type-iv-kollagens zur änderung der zell- und gewebewechselwirkung
DE69425870D1 (de) Entwicklungseinheit mit Vorrichtung zur Regelung der Entwicklermenge
HUP9901757A2 (hu) Az integrin szabályozás/jelzés citoplazmás modulátorai
DE9319049U1 (de) Systemsteuerung zur Reduzierung des Energieverbrauchs von elektronischen Geräten im Standby-Betrieb
ATE203858T1 (de) Verfahren zum erfassen des energieeinsparpotentials eines elektrischen energieverbrauchersystems und verfahren zum betreiben eines elektrischen engergieverbrauchersystems
FR2261005A1 (en) 5-Amino-indane-1-carboxylic acid derivs - prepd. by hydrolysis of their lower-alkyl esters
JPS6462072A (en) Picture reader
DE59908293D1 (de) Polymermischungen zur Verbesserung der Schmierwirkung von Mitteldestillaten
DE69216253T2 (de) 2-(2-benzo b thienyl)-3-methoxyacrylat- und -2-iminoacetat-derivate zur verwendung als pestizide
BR7801924U (pt) Monitor para controle de nìvel de água
Wortmann Medical studies of the circadian rhythm and the behaviour of station personnel in an Antarctic research station

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee